Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.50 |
| ▸ | CHUK | O15111 | 9/20 | 0.50 |
| ▸ | IKBKG | Q9Y6K9 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 6/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492936 | 1.00 | IKBKB (0.50) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL4492941 | 1.00 | IKBKB (0.50) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL4478744 | 0.73 | IKBKB (0.48) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL4478740 | 0.73 | IKBKB (0.48) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL3472229 | 0.73 | IKBKB (0.54) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL3471384 | 0.72 | KCNH2 (0.48) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL13633647 | 0.71 | IKBKB (0.48) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL3472274 | 0.71 | IKBKB (0.48) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL13633704 | 0.71 | IKBKB (0.48) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL16200004 | 0.71 | IKBKB (0.48) | IKBKBCHUKIKBKGMEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | IKBKB 2/4885CHUK 3/4885IKBKG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.